cmRNAbone Project's Success Sets Stage for Innovative Bone Regeneration Therapies

After four and a half years of dedicated research, the cmRNAbone project has successfully concluded. The final consortium meeting, hosted by the coordinating institution AO Research Institute Davos, took place in the Swiss town on June 19, 2024.

Through the integration of genetic research, advanced nano- and biotechnology, and 3D printing, the cmRNAbone consortium has achieved its mission of pioneering a new therapy for bone regeneration. Our team of experts from across Europe has developed chemically modified RNAs capable of producing specific proteins for the bone regeneration process. Using a specialised 3D printer designed by cmRNAbone, these RNAs can subsequently be printed and implanted, allowing for the in-laboratory production of all necessary materials without requiring input from the patient.

Since bone is the second most transplanted tissue after blood, the impact of the cmRNAbone bone therapy is vast. “We are utterly proud to have paved the way for a therapy that can improve the lives of countless people with severe traumatic injuries or bone-degenerating diseases such as osteoporosis,” says project coordinator Prof Martin Stoddart. “By addressing the needs of healthcare systems and patients and ensuring the therapy is economically viable, we have succeeded where others have struggled. We are confident that this treatment will shape the future of bone regeneration.”

To showcase the project's main accomplishments, the cmRNAbone consortium has published a new video. You can view it on our homepage and on YouTube.

The cmRNAbone consortium at the final meeting in Davos, Switzerland